Screener
CG Oncology CGON Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(139,258) | $(75,878) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,691 | 180 |
| Stock-based compensation expense | 20,808 | 12,158 |
| Unrealized losses (gains) on short-term investments | 4,668 | (2,166) |
| Non-cash interest expense (income) | 92 | (675) |
| Non-cash lease expense | 38 | 13 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's stock-based comp?
- CG Oncology (CGON) reported stock-based comp of $14.33M in Q2 2026.
- How has CG Oncology's stock-based comp changed year-over-year?
- CG Oncology's stock-based comp increased by 104.6% year-over-year, from $7.01M to $14.33M.
- What is the long-term trend for CG Oncology's stock-based comp?
- Over 2 years (2023 to 2025), CG Oncology's stock-based comp has grown at a 317.8% compound annual growth rate (CAGR), from $1.53M to $26.68M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about CG Oncology's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude